中国医药健康产业股份有限公司 董事和高级管理人员所持本公司股份及其变动管理办法 （2025 年修订） 第一章 总 则 第一条 为贯彻落实《中华人民共和国公司法》《中华人民共 和国证券法》（以下简称"《证券法》"）《上市公司董事和高级管 理人员所持本公司股份及其变动管理规则》《上海证券交易所上 市公司自律监管指引第 8 号——股份变动管理》《上海证券交易 所上市公司自律监管指引第 15 号——股东及董事、高级管理人 员减持股份》等法律法规的规定以及《中国医药健康产业股份有 限公司章程》（以下简称"《公司章程》"）有关规定，加强对中 国医药健康产业股份有限公司（以下简称"公司"或"本公司"）董 事和高级管理人员所持本公司股份及其变动的管理，结合公司实 际情况，特制定本办法。 第二条 公司董事和高级管理人员应该遵守本办法。 1 第二章 交易禁止和限制 第五条 公司董事和高级管理人员所持本公司股份在下列 情形下不得转让： （一）本公司股票上市交易之日起一年内； （二）董事和高级管理人员离职后半年内； （三）公司因涉嫌证券期货违法犯罪，被中国证监会立案调 查或者被司法机关立案侦查，或者被行政处罚、判处刑罚未满六 个月的 ...

中国医药健康产业股份有限公司 银行间债券市场债务融资工具 信息披露事务管理制度 （2025 年修订） 目 录 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 信息披露的基本原则 | 1 | | 第三章 | 信息披露的内容及标准 | 2 | | 第四章 | 未公开信息的传递、审核、披露流程 | 7 | | 第五章 | 信息披露工作的管理 | 8 | | 第六章 | 财务管理和会计核算的内部控制及监督机制 | 10 | | 第七章 | 信息披露相关文件、资料的档案管理 | 11 | | 第八章 | 信息披露的保密措施 | 11 | | 第九章 | 违规责任的追究措施 | 11 | | 第十章 | 附则 | 12 | 第一章 总则 第一条 为规范中国医药健康产业股份有限公司（以下 简称"公司"）在银行间债券市场发行债务融资工具的对外 信息披露行为，保护投资者合法权益，根据《中华人民共和 国公司法》《中华人民共和国证券法》《银行间债券市场非 金融企业债务融资工具管理办法》《银行间债券市场非金融 企业债务融资工具信息披露规则》等法律法规及《中国医药 健康产业股份有限公司章程》（ ...

中国医药健康产业股份有限公司 信息披露事务管理制度 （2025 年修订） | 第七章附则 23 | | --- | 第一章 总则 第一条 为规范中国医药健康产业股份有限公司（以下 简称"公司"）及其他信息披露义务人的信息披露行为，加强 信息披露事务管理，促进公司依法规范运作，切实维护公司 和投资者的合法权益，根据《中华人民共和国公司法》《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公 司信息披露管理办法》（以下简称"《管理办法》"）《上海 证券交易所股票上市规则》（以下简称"《上市规则》"）《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》 等法律法规及《中国医药健康产业股份有限公司章程》（以 下简称"《公司章程》"）的规定，制定本制度。 第二条 本制度所称"股票及其衍生品种"是指股票、存 托凭证、可转换为股票的公司债券（以下简称"可转换公司债 券"）和其他衍生品种。 第三条 本制度所称"信息"是指所有可能对公司股票及 其衍生品种交易价格产生较大影响而投资者尚未得知的信 息，以及中国证券监督管理委员会（以下简称"中国证监会"） 及其派出机构和上海证券交易所等证券监管机构的监管要 求或公 ...

近日，中国医药健康产业股份有限公司（以下简称"公司"）下属子公司湖北 科益药业股份有限公司（以下简称"科益药业"）收到国家药品监督管理局（以 下简称"国家药监局"）核准签发的夫西地酸乳膏（以下简称"该药品"）《药品注 册证书》，现将有关情况公告如下： 一、注册证书基本信息 药品名称：夫西地酸乳膏 受理号：CYHS2402156 证券代码：600056 证券简称：中国医药 公告编号：临 2025-082 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证书编号：2025S03152 剂型：乳膏剂 规格：2%（15g:0.3g，按 C31H48O6计） 上市许可持有人：湖北科益药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 （一）夫西地酸乳膏主要用于由葡萄球菌、链球菌、痤疮丙酸杆菌、极小棒 状杆菌及其他对夫西地酸敏感的细菌引起的皮肤感染，于 1980 ...

Core Viewpoint - The company China Pharmaceutical has announced that its subsidiary, Koyi Pharmaceutical, has received a drug registration certificate for Fusidic Acid Cream [1] Group 1 - The drug registration certificate is a significant milestone for Koyi Pharmaceutical, indicating regulatory approval for the product [1] - Fusidic Acid Cream is expected to enhance the company's product portfolio and market presence in the pharmaceutical industry [1]

Core Viewpoint - The quality management team of Shaanxi Buchang Pharmaceutical, a subsidiary of Buchang Pharmaceutical (603858), won the first prize at the 46th China Pharmaceutical Quality Management Association QC team release conference, highlighting the company's strong foundation and excellence in quality management [1]. Group 1 - The Shaanxi Buchang Pharmaceutical QC team has cultivated a group of outstanding quality management team leaders, providing solid support for the implementation of projects [1]. - Since its establishment in 2019, the QC team has consistently aimed for "continuous improvement in quality management" and has made steady progress [1].

Group 1 - The core viewpoint of the article highlights the strategic discussions between China General Technology and Luzhou Laojiao Co., Ltd. regarding deepening existing business collaborations and exploring opportunities in the health industry [1] - Both parties engaged in in-depth exchanges on brand resource synergy and innovations in e-commerce business models, reaching a preliminary consensus [1] - The discussions are aimed at laying the foundation for further strategic cooperation and expanding business areas in the future [1]

Core Insights - The CXO (Contract X Organization) model allows pharmaceutical companies to outsource drug development, production, or sales to specialized institutions, enhancing efficiency and reducing costs while sharing the benefits of pharmaceutical innovation [1][2][4] - The global CXO market is projected to reach $196.6 billion by 2025, with a CAGR of 14.0% from 2021 to 2025, while the Chinese market is expected to grow to 247.7 billion yuan, with a remarkable CAGR of 26.56% from 2020 to 2025 [1][7][9] - Recent policies in China, such as the MAH (Marketing Authorization Holder) system, are optimizing resource allocation and encouraging innovation, providing a robust support system for the CXO industry [5][10] CXO Industry Overview - CXO encompasses various outsourcing services including CRO (Contract Research Organization), CMO (Contract Manufacturing Organization), CDMO (Contract Development and Manufacturing Organization), and CSO (Contract Sales Organization) [2][4] - The CXO industry is characterized by a full-process collaboration model that integrates services from early research to commercial production, significantly improving client R&D efficiency [4][10] Policy Analysis - Recent Chinese policies have created a favorable environment for the CXO industry, promoting innovation and optimizing the pharmaceutical supply chain [5][10] - The implementation of the MAH system has separated drug marketing and production licenses, enhancing specialization and reducing redundant investments [5][10] Global Market Trends - The global CXO market is experiencing rapid expansion, driven by increased R&D investments from innovative pharmaceutical companies [6][9] - By 2025, the global CRO market is expected to reach approximately $98 billion, while the CDMO market is projected to reach $99 billion, indicating strong growth potential [6][9] Chinese Market Dynamics - China's CXO market is rapidly expanding, with a projected market size increase from 76.3 billion yuan in 2020 to 247.7 billion yuan by 2025, reflecting a strong domestic market vitality [7][9] - In the first eight months of 2025, domestic innovative drug financing reached $7.75 billion, a year-on-year increase of 89%, highlighting the growing investment interest in the sector [9][10] Competitive Landscape - The Chinese CXO industry features a clear competitive hierarchy, with leading companies like WuXi AppTec and Kanglong Chemical expanding their market share through comprehensive service capabilities [10] - The first-tier companies are establishing a global delivery system, while second-tier companies are focusing on niche areas to build competitive advantages [10] Future Development Trends - The CXO industry is expected to evolve around three main directions: technological advancement, global operations, and ecosystem integration [10][12] - Leading companies will focus on high-tech areas such as ADC and gene therapy, while also enhancing their global operational resilience [12][13] - The integration of AI in drug development will drive new service models and reshape the competitive landscape, with larger firms consolidating their positions while smaller firms must specialize to survive [14]

Core Insights - In April 2025, China's import volume of medicinal materials and pharmaceuticals reached 38,500 tons, reflecting a year-on-year growth of 0.2% [1] - The import value amounted to $4.089 billion, showing a year-on-year decline of 11.2% [1] - In the same month, China's export volume of medicinal materials and pharmaceuticals was 150,000 tons, with a year-on-year increase of 17.8% [1] - The export value stood at $2.221 billion, marking a year-on-year growth of 7.6% [1] Import Data Summary - Import volume in April 2025: 38,500 tons [1] - Year-on-year growth in import volume: 0.2% [1] - Import value in April 2025: $4.089 billion [1] - Year-on-year decline in import value: 11.2% [1] Export Data Summary - Export volume in April 2025: 150,000 tons [1] - Year-on-year growth in export volume: 17.8% [1] - Export value in April 2025: $2.221 billion [1] - Year-on-year growth in export value: 7.6% [1]

Group 1 - Pinggao Electric reported a 6.98% increase in revenue to 8.436 billion yuan and a 14.62% increase in net profit to 982 million yuan for the first three quarters of 2025 [1] - Wanchen Group achieved a 77.37% increase in revenue to 36.562 billion yuan and a staggering 917.04% increase in net profit to 855 million yuan for the first three quarters of 2025 [2] - Xintian's revenue decreased by 10.42% to 481 million yuan, with a net profit decline of 35.19% to 91.9 million yuan for the first three quarters of 2025 [3] Group 2 - Chuangye Heima reported a revenue drop of 35.68% to 102 million yuan and a net loss of 24.93 million yuan for the first three quarters of 2025 [4] - Huaxin New Materials saw a 16.11% increase in revenue to 265 million yuan and an 18.56% increase in net profit to 40.81 million yuan for the first three quarters of 2025 [5] - Meihua Medical's revenue increased by 3.28% to 1.194 billion yuan, but net profit fell by 19.25% to 208 million yuan for the first three quarters of 2025 [6] Group 3 - Silica Technology reported a 24.30% increase in revenue to 2.651 billion yuan and a 44.63% increase in net profit to 229 million yuan for the first three quarters of 2025 [7] - Anada experienced a revenue decline of 6.03% to 1.31 billion yuan and a net loss of 46.37 million yuan for the first three quarters of 2025 [8] - StarNet Ruijie achieved a 19.20% increase in revenue to 14.168 billion yuan and a 31.06% increase in net profit to 344 million yuan for the first three quarters of 2025 [9] Group 4 - New Link Electronics reported a revenue decrease of 0.37% to 550 million yuan but a significant net profit increase of 421.43% to 535 million yuan for the first three quarters of 2025 [10] - Tianyin Electromechanical's revenue fell by 22.75% to 581 million yuan, with a net profit decline of 56.10% to 24.27 million yuan for the first three quarters of 2025 [11] - Hengtong Co. reported a revenue decrease of 39.29% to 1.05 billion yuan, but a net profit increase of 78.33% to 176 million yuan for the first three quarters of 2025 [12] Group 5 - Xigao Institute achieved a 15.05% revenue increase to 651 million yuan and a 21.28% net profit increase to 198 million yuan for the first three quarters of 2025 [13] - Good Housewife reported a revenue decrease of 0.91% to 1.059 billion yuan and a net profit decline of 24.79% to 143 million yuan for the first three quarters of 2025 [14] - China Pharmaceutical's subsidiary received approval for Vitamin B6 injection, indicating a positive development in its product pipeline [20] Group 6 - Xi Zhong Technology received approval for the issuance of convertible bonds, indicating potential for future capital raising [22] - Chengda Bio signed a strategic cooperation agreement with the Chinese Academy of Microbiology, focusing on infectious disease prevention [25] - Fuyuan Pharmaceutical received a drug registration certificate for Dydrogesterone tablets, enhancing its product offerings [26] Group 7 - Zhehai Deman received 8.1202 million yuan in land acquisition compensation, indicating a successful resolution of land-related issues [27] - Zhongjin Irradiation announced the resignation of its deputy general manager, indicating potential changes in management [29] - Hendi Pharmaceutical received a drug registration certificate for Febuxostat tablets, expanding its product portfolio [30] Group 8 - David Medical's subsidiary received a medical device registration certificate for a surgical stapler, enhancing its product offerings [32] - Liaoning Energy announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [34] - Fengyuan Co. signed a framework agreement for the supply of lithium iron phosphate, indicating growth in its supply chain [35] Group 9 - Shengda Resources announced the resumption of construction at a mining site, indicating recovery from previous operational disruptions [37] - Shiyuan Co. reported a revenue increase of 5.45% to 18.087 billion yuan, but a net profit decline of 6.81% to 867 million yuan for the first three quarters of 2025 [39] - Feilida reported a revenue decrease of 6.81% to 4.659 billion yuan, but a net profit increase of 49.1% to 33.19 million yuan for the first three quarters of 2025 [40] Group 10 - Changyuan Donggu reported a revenue increase of 29.75% to 1.648 billion yuan and a net profit increase of 76.71% to 274 million yuan for the first three quarters of 2025 [41] - Liyuanheng reported a net profit of 47.49 million yuan for the first three quarters of 2025, indicating stable performance [42] - Fangyuan Co. reported a net loss of 121 million yuan for the first three quarters of 2025, indicating challenges in its operations [43] Group 11 - China Mobile reported a revenue increase of 0.4% to 794.7 billion yuan and a net profit increase of 4% to 115.4 billion yuan for the first three quarters of 2025 [44] - Huangshanghuang reported a revenue decrease of 5.08% to 1.379 billion yuan but a net profit increase of 28.59% to 101 million yuan for the first three quarters of 2025 [46] - Youcai Resources announced plans to invest approximately 150 million yuan in a new materials production base project [47] Group 12 - Huawei Technology announced plans to invest up to 20 million euros in two German subsidiaries [49] - China Shipbuilding projected a net profit increase of 144.42% to 170.85% for the first three quarters of 2025, indicating strong performance [51] - Aeston's subsidiary plans to transfer a 48% stake in a company for 245 million yuan, indicating strategic divestment [52] Group 13 - Jinxinno plans to raise up to 292 million yuan through a private placement, indicating potential for expansion [53] - China Power Construction reported a 5.04% increase in new contract amounts to 904.527 billion yuan for the first three quarters of 2025 [54] - Helitai reported a net profit increase of 101.45% to 17.81 million yuan for the first three quarters of 2025 [55] Group 14 - Xuefeng Technology reported a revenue decrease of 8.28% to 4.183 billion yuan and a net profit decline of 34.6% to 394 million yuan for the first three quarters of 2025 [57] - Juzhi Technology reported a revenue increase of 21.40% to 615 million yuan and a net profit increase of 33.78% to 82.47 million yuan for the first three quarters of 2025 [59] - Jinxi Axle reported a revenue decrease of 0.11% to 872 million yuan but a net profit increase of 268.03% to 22.11 million yuan for the first three quarters of 2025 [60] Group 15 - Longsheng Technology reported a revenue increase of 10.13% to 1.810 billion yuan and a net profit increase of 36.89% to 210 million yuan for the first three quarters of 2025 [62] - Shannon Chip Creation announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [63]